• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激酶抑制剂界面中的 C─H⋯O 氢键。

C─H⋯O hydrogen bonds in kinase-inhibitor interfaces.

机构信息

Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, USA.

University of Warsaw, Warsaw, Poland.

出版信息

IUBMB Life. 2020 Jun;72(6):1233-1242. doi: 10.1002/iub.2282. Epub 2020 Apr 9.

DOI:10.1002/iub.2282
PMID:32271995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7641297/
Abstract

C─H⋯O hydrogen bonds constitute a unique class of cohesive interactions. Their properties are similar to those of canonical H-bonds, although their energy is significantly lower, typically in the 0.5-2.5 kcal/mol range. Polarised C─H groups, such as those adjacent to electronegative groups, or within aromatic moieties, are particularly strong donors. C─H⋯O bonds are ubiquitous in nucleic acids and in proteins, notably stabilizing the β-sheet secondary structure. They have also been observed in numerous protein-ligand interactions. Here, we analysed crystal structures, deposited in the Protein Data Bank, of complexes of FDA-approved protein kinase inhibitors with cognate kinases, to assess the possible role of C─H ⋯O hydrogen bonds. The conserved hinge motif of protein kinases with two solvent-exposed carbonyl groups and one exposed backbone amide, is well known to be involved in canonical H-bonding with inhibitors. We now find that in virtually all complexes where the inhibitor interacts with the hinge backbone, at least one of the hinge carbonyl groups accepts an H-bond from a C─H inhibitor group, which is either aromatic or adjacent to an electronegative group. These observations are important for design of hinge-binding scaffolds of novel kinase inhibitors for therapeutic use.

摘要

C─H⋯O 氢键构成了一类独特的结合相互作用。它们的性质与经典的氢键相似,尽管它们的能量显著较低,通常在 0.5-2.5 kcal/mol 范围内。带极性的 C─H 基团,如紧邻电负性基团的基团,或在芳香族部分内的基团,是特别强的供体。C─H⋯O 键在核酸和蛋白质中无处不在,特别是稳定β-折叠二级结构。它们也在许多蛋白质-配体相互作用中被观察到。在这里,我们分析了储存在蛋白质数据库中的 FDA 批准的蛋白激酶抑制剂与同源激酶复合物的晶体结构,以评估 C─H ⋯O 氢键的可能作用。蛋白激酶的保守铰链模体具有两个暴露在溶剂中的羰基和一个暴露的骨架酰胺,众所周知,它与抑制剂参与经典氢键。我们现在发现,在几乎所有抑制剂与铰链骨架相互作用的复合物中,至少有一个铰链羰基接受来自抑制剂的 C─H 基团的氢键,该基团要么是芳香族的,要么紧邻电负性基团。这些观察结果对于设计用于治疗的新型激酶抑制剂的铰链结合支架很重要。

相似文献

1
C─H⋯O hydrogen bonds in kinase-inhibitor interfaces.激酶抑制剂界面中的 C─H⋯O 氢键。
IUBMB Life. 2020 Jun;72(6):1233-1242. doi: 10.1002/iub.2282. Epub 2020 Apr 9.
2
Kinase hinge binding scaffolds and their hydrogen bond patterns.激酶铰链结合支架及其氢键模式。
Bioorg Med Chem. 2015 Oct 1;23(19):6520-7. doi: 10.1016/j.bmc.2015.08.006. Epub 2015 Aug 29.
3
Newly identified C-H⋯O hydrogen bond in histidine.组氨酸中新发现的 C-H⋯O 氢键。
Phys Chem Chem Phys. 2022 Aug 17;24(32):19233-19251. doi: 10.1039/d2cp02048c.
4
Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors.芳香环作为蛋白激酶抑制剂分子识别的分子决定因素。
Molecules. 2021 Mar 22;26(6):1776. doi: 10.3390/molecules26061776.
5
Strong and weak hydrogen bonds in protein-ligand complexes of kinases: a comparative study.激酶蛋白-配体复合物中的强氢键和弱氢键:一项比较研究。
Amino Acids. 2008 May;34(4):617-33. doi: 10.1007/s00726-007-0015-4. Epub 2008 Jan 8.
6
Evaluation of C-H cdots, three dots, centered O hydrogen bonds in native and misfolded proteins.天然和错误折叠蛋白质中C-H…O氢键的评估。
J Mol Biol. 2002 Sep 20;322(3):497-503. doi: 10.1016/s0022-2836(02)00785-4.
7
Kinase inhibitors and the case for CH...O hydrogen bonds in protein-ligand binding.激酶抑制剂与蛋白质-配体结合中CH...O氢键的情况。
Proteins. 2002 Dec 1;49(4):567-76. doi: 10.1002/prot.10259.
8
A structural role for tryptophan in proteins, and the ubiquitous Trp C-H...O=C (backbone) hydrogen bond.色氨酸在蛋白质中的结构作用,以及普遍存在的 Trp C-H…O=C(骨架)氢键。
Acta Crystallogr D Struct Biol. 2024 Jul 1;80(Pt 7):551-562. doi: 10.1107/S2059798324005515. Epub 2024 Jun 28.
9
Halogen bonds involved in binding of halogenated ligands by protein kinases.蛋白质激酶与卤化配体结合中涉及的卤键。
Acta Biochim Pol. 2016;63(2):203-14. doi: 10.18388/abp.2015_1106. Epub 2016 Apr 20.
10
Multicomponent supramolecular assemblies of 1(2H)-Phthalazinone and Tetrafluoroterephthalic acid: Understanding the role of hydrogen bonding on the structure and properties using experimental and computational analyses.1(2H)-酞嗪酮和四氟对苯二甲酸的多组分超分子组装:通过实验和计算分析了解氢键对结构和性能的作用。
Spectrochim Acta A Mol Biomol Spectrosc. 2020 Mar 5;228:117689. doi: 10.1016/j.saa.2019.117689. Epub 2019 Oct 30.

引用本文的文献

1
Scaffold-Hopping Design and Synthesis of Thieno[3,2-]pyrimidines: Anticancer Activity, Apoptosis Induction, and In Silico Inhibition of CDKs.噻吩并[3,2 -]嘧啶的骨架跃迁设计与合成:抗癌活性、凋亡诱导及对细胞周期蛋白依赖性激酶的计算机模拟抑制
Int J Mol Sci. 2025 Sep 2;26(17):8528. doi: 10.3390/ijms26178528.
2
AI-Driven Design and Development of Nontoxic DYRK1A Inhibitors.人工智能驱动的无毒DYRK1A抑制剂的设计与开发
J Med Chem. 2025 May 22;68(10):10346-10364. doi: 10.1021/acs.jmedchem.5c00512. Epub 2025 May 3.
3
CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets.

本文引用的文献

1
Properties of FDA-approved small molecule protein kinase inhibitors.已批准用于临床的小分子蛋白激酶抑制剂的特性。
Pharmacol Res. 2019 Jun;144:19-50. doi: 10.1016/j.phrs.2019.03.006. Epub 2019 Mar 13.
2
Targeting Pim Kinases and DAPK3 to Control Hypertension.靶向 Pim 激酶和 DAPK3 以控制高血压。
Cell Chem Biol. 2018 Oct 18;25(10):1195-1207.e32. doi: 10.1016/j.chembiol.2018.06.006. Epub 2018 Jul 19.
3
Overview of refinement procedures within REFMAC5: utilizing data from different sources.REFMAC5 精修过程概述:利用来自不同来源的数据。
细胞周期蛋白依赖性激酶2和4:细胞周期功能演变为独特的、具有催化活性的构象,提供药物靶点。
JACS Au. 2024 May 14;4(5):1911-1927. doi: 10.1021/jacsau.4c00138. eCollection 2024 May 27.
4
Crystal Clear: Decoding Isocyanide Intermolecular Interactions through Crystallography.一清二楚:通过晶体学解析异腈分子间相互作用
J Org Chem. 2024 Jan 19;89(2):957-974. doi: 10.1021/acs.joc.3c02038. Epub 2024 Jan 4.
5
Synthesis and evaluation of potent (iso)ellipticine-based inhibitors of MYLK4 accessed expeditious synthesis from isoquinolin-5-ol.基于(异)玫瑰树碱的MYLK4强效抑制剂的合成与评价,可通过异喹啉-5-醇进行快速合成。
RSC Adv. 2023 Oct 30;13(45):31595-31601. doi: 10.1039/d3ra06600b. eCollection 2023 Oct 26.
6
C-H Groups as Donors in Hydrogen Bonds: A Historical Overview and Occurrence in Proteins and Nucleic Acids.C-H 基团作为氢键供体:历史概述及在蛋白质和核酸中的存在。
Int J Mol Sci. 2023 Aug 24;24(17):13165. doi: 10.3390/ijms241713165.
7
Discovery of a novel cyclin-dependent kinase 8 inhibitor with an oxindole core for anti-inflammatory treatment.发现一种新型以吲哚酮为核心的细胞周期蛋白依赖性激酶 8 抑制剂,可用于抗炎治疗。
Biomed Pharmacother. 2022 Feb;146:112459. doi: 10.1016/j.biopha.2021.112459. Epub 2021 Dec 22.
Acta Crystallogr D Struct Biol. 2018 Mar 1;74(Pt 3):215-227. doi: 10.1107/S2059798318000979. Epub 2018 Mar 2.
4
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.用于治疗炎症性和肿瘤性疾病的 Janus 激酶(JAK)抑制剂
Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26.
5
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.基于小分子蛋白激酶抑制剂与酶复合物的结构对其进行分类。
Pharmacol Res. 2016 Jan;103:26-48. doi: 10.1016/j.phrs.2015.10.021. Epub 2015 Oct 31.
6
Kinase hinge binding scaffolds and their hydrogen bond patterns.激酶铰链结合支架及其氢键模式。
Bioorg Med Chem. 2015 Oct 1;23(19):6520-7. doi: 10.1016/j.bmc.2015.08.006. Epub 2015 Aug 29.
7
Protein-kinase inhibitors: A new treatment pathway for autoimmune and inflammatory diseases?蛋白激酶抑制剂:自身免疫性疾病和炎症性疾病的新治疗途径?
Reumatol Clin. 2016 Mar-Apr;12(2):91-9. doi: 10.1016/j.reuma.2015.06.004. Epub 2015 Aug 14.
8
A historical overview of protein kinases and their targeted small molecule inhibitors.蛋白激酶及其靶向小分子抑制剂的历史概述。
Pharmacol Res. 2015 Oct;100:1-23. doi: 10.1016/j.phrs.2015.07.010. Epub 2015 Jul 21.
9
Carbon-oxygen hydrogen bonding in biological structure and function.碳-氧-氢键在生物结构和功能中的作用。
J Biol Chem. 2012 Dec 7;287(50):41576-82. doi: 10.1074/jbc.R112.418574. Epub 2012 Oct 9.
10
Targeting cancer with small-molecular-weight kinase inhibitors.使用小分子激酶抑制剂靶向治疗癌症。
Methods Mol Biol. 2012;795:1-34. doi: 10.1007/978-1-61779-337-0_1.